KR100732614B1 - Pharmaceutical composition for the prevention or treatment of obesity or diabetic disease comprising blowfish extract - Google Patents
Pharmaceutical composition for the prevention or treatment of obesity or diabetic disease comprising blowfish extract Download PDFInfo
- Publication number
- KR100732614B1 KR100732614B1 KR1020050071062A KR20050071062A KR100732614B1 KR 100732614 B1 KR100732614 B1 KR 100732614B1 KR 1020050071062 A KR1020050071062 A KR 1020050071062A KR 20050071062 A KR20050071062 A KR 20050071062A KR 100732614 B1 KR100732614 B1 KR 100732614B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- obesity
- blowfish
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 241001441724 Tetraodontidae Species 0.000 title claims abstract description 37
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 230000002265 prevention Effects 0.000 title claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 208000008589 Obesity Diseases 0.000 title abstract description 23
- 235000020824 obesity Nutrition 0.000 title abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 13
- 241000251468 Actinopterygii Species 0.000 claims abstract description 28
- 239000000872 buffer Substances 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000004821 distillation Methods 0.000 claims description 7
- 238000000998 batch distillation Methods 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 8
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 235000021590 normal diet Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000003579 anti-obesity Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000004136 fatty acid synthesis Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241001137251 Corvidae Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002816 gill Anatomy 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 241001098666 Pterois volitans Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 241000217821 Takifugu rubripes rubripes Species 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- -1 acarboose Chemical compound 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000001577 simple distillation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 제독된 복어를 증류하여 얻어지는 복어의 수추출물을 포함하는 비만 또는 당뇨성 질환의 예방 또는 치료용 조성물을 제공한다.The present invention provides a composition for the prevention or treatment of obesity or diabetic disease, including the water extract of the puffer fish obtained by distilling the puffer fish.
복어 추출물, 비만, 당뇨성 Pufferfish extract, obesity, diabetic
Description
도 1은 23주간 복어 추출물을 투여한 생쥐로부터 간을 적출하여 내고, 이를 시료로 하여 FAS (fatty acid synthase)에 대하여 웨스턴 블롯 분석실험을 한 결과를 나타내는 도면이다.1 is a view showing the results of Western blot analysis of the fatty acid synthase (FAS) from the liver was extracted from the mice to which the pufferfish extract was administered for 23 weeks, as a sample.
도 2는 본 발명의 복어 추출물을 30주 동안 생쥐에 투여하고 매 1 주일 마다 체중을 측정하여 체중의 변화를 관찰한 결과를 나타내는 도면이다.2 is a view showing the results of observing the change in weight by administering the blowfish extract of the present invention to the mouse for 30 weeks and measuring the weight every week.
본 발명은 복어 추출물을 포함하는 비만 또는 당뇨성 질환의 예방 또는 치료용 약학 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for the prevention or treatment of obesity or diabetic disease comprising a blowfish extract.
당뇨병 (Diabetes mellitus)이란 췌장에 있는 랑게르한스 (Langerhans)섬의 β 세포에서 분비되는 인슐린 (insulin)의 생리작용이 저조하거나 인슐린-수용체 (insulin-receptor)의 수가 적어 인슐린의 생리적 기능이 충분하지 못할 때 나타나는 고혈당증의 한 증상으로 요중에 당이 검출되는 증상을 말한다. 당뇨가 유발되면 인슐린과 글루카곤(glucagon)의 분비상태가 교란되어 탄수화물뿐만 아니라 단백질 및 지질대사 등 생체 내 대사 조절기능에 이상이 생겨 여러 가지 대사질환이 나타나게 되며, 당뇨증상이 오래 지속되면 모세혈관의 상피 세포막의 비후가 일어나 순환기계 등에 많은 합병증의 유발이 문제시되고 있다.Diabetes mellitus is when the physiological function of insulin released by β cells of the Langerhans islet in the pancreas is poor or the number of insulin-receptors is low, resulting in insufficient insulin physiological function. It is a symptom of hyperglycemia that occurs when urine has sugar detected. When diabetes is induced, the secretion state of insulin and glucagon is disturbed, causing abnormal metabolic control functions such as protein and lipid metabolism as well as carbohydrates, resulting in various metabolic diseases. Thickening of epithelial cell membranes causes many complications such as the circulatory system.
진성 당뇨병 (Diabetes mellitus)은 두 가지 유형으로 특징지워지는데, 제 1형 당뇨병 (type 1 diabetes mellitus)은 혈액 내의 글루코스 조절 호르몬인 인슐린 (insulin)의 분비 결핍으로 야기되며, 주로 10 내지 20대의 젊은 연령층에서 발병되기 때문에 소아당뇨병 (juvenile diabetes)이라 불리우기도 한다. 제 2형 당뇨병 (type 2 diabetes mellitus)은 주로 40대 이후에 발병되며, 우리나라 당뇨병 환자의 대부분을 차지한다. 제 1형과는 달리 성인형 당뇨병이라 불리우며 발병 원인은 아직 명확히 밝혀져 있지 않으나, 유전적인 요인과 환경적 요소가 함께 관여되어 발생하는 것으로 알려져 있는데, 제 2형 당뇨병의 병인으로 췌장 베타세포에서 인슐린 분비의 장애와 표적세포에서 인슐린 작용의 결함(인슐린 저항성)이 모두 관찰된다. Diabetes mellitus is characterized by two types, type 1 diabetes mellitus, which is caused by a lack of secretion of insulin, a glucose-regulating hormone in the blood, mainly younger people in their 10s to 20s. It is also called juvenile diabetes because it occurs in women.
당뇨병 치료에 있어서 가장 중요한 목표는 혈당치를 가능한 정상치에 가깝게 조절하는 것이며, 치료 방법으로 약물요법, 식이요법 및 운동요법을 실시하고 있다. 현재 제 1형 및 제 2형 당뇨병 환자에게 사용되는 경구혈당강하제로 α-글루코시다아제 (α-glucosidase) 억제제, 설포닐우레아 (sulfonylurea) 제제 및 비구아니드 (biguanide) 제제가 있으며, α-글루코시다아제 억제제는 섭취한 식이 중의 탄수화물의 소화와 흡수를 지연시켜 식후 혈당 및 혈중 인슐린의 상승을 감소시킴 으로써 당뇨병의 치료효과를 나타낸다. α-글루코시다아제 저해제는 고인슐린혈증이나 저혈당을 유발하지 않고, 인슐린분비를 촉진시키며 글루카곤 분비를 억제하는 글루카곤-유사-펩티드-1 (glucagon-like peptide-1)의 소장에서의 분비를 촉진하는 장점을 가지고 있다 (Mooradian, A.D., Thurman, J.E., Drugs, 57, pp19-29, 1999; Baron, A.D. Diabetes Research and Clinical Practice, 40, ppS54-S55, 1998). 현재 임상에서 사용하고 있는 것으로는 아카보스 (acarbose), 보길리보스 (voglibose) 및 미글리톨 (miglitol) 등이 있으나, α-글리코시다아제 저해제를 장기간 복용한 경우 일부 환자에 있어서 복부 팽만감, 구토 설사 등 부작용을 나타낼 수 있어 그 사용이 제한될 수 있다 (Hanefeld M., Journal of Diabetes and its Complications, 12, pp228-237, 1998). The most important goal in the treatment of diabetes is to control blood glucose levels as close to normal as possible, and therapies include pharmacotherapy, diet and exercise therapy. Oral hypoglycemic agents currently used in patients with type 1 and
현재까지 당뇨병의 완치법은 확립되어 있지 않고, 약물치료의 부작용 때문에 약물사용에 제한점이 많아 천연물로부터 당뇨병치료제를 탐색하려는 연구가 활발히 진행되고 있으며, WHO(1990)에서도 당뇨병에 효과가 있으며 부작용이 적은 천연물의 이용을 적극 추천하였다 (Grover J.K., Vats. V., Rathi. S.S., Journal of Ethnopharmacology, 73, pp461-470, 2000). To date, there is no cure for diabetes, and there are many researches to search for diabetes drugs from natural products due to the side effects of drug treatments, and WHO (1990) is effective for diabetes and has fewer side effects. The use of natural products is highly recommended (Grover JK, Vats. V., Rathi. SS, Journal of Ethnopharmacology, 73, pp 461-470, 2000).
또한, 비만의 원인으로는 환경 및 사회의 변화에 따른 고지방, 고열량의 식생활 및 편리함을 추구하는 문명의 발달로 인한 운동부족과 그외 내분비이상이나 병리생리학적인 이상을 들 수 있다. 또한 비만의 유전적 요인이 중요한 원인으로 작용한다는 것은 비만이 가계와 연관되어 집중 발생한다는 사실에서 알 수 있는데 환경적 요인 외에 유전적 요인이 비만증의 발생에 적어도 30∼50% 정도의 영향을 미친다고 알려져 있다. In addition, the causes of obesity include the lack of exercise and other endocrine or pathophysiological abnormalities caused by the development of civilization in pursuit of high-fat, high-calorie diet and convenience according to environmental and social changes. In addition, the genetic factor of obesity is an important cause of the fact that obesity is related to households, and in addition to environmental factors, genetic factors affect at least 30-50% of the occurrence of obesity. Known.
비만을 치료하고 예방하는 방법은 여러 나라에서 활발하게 다각적인 측면에서 연구되고 있는데 현재 실행되고 있는 방법으로 음식물의 섭취량을 억제하여 에너지소비를 줄이는 식이요법, 운동을 통해 에너지를 발산시키는 운동요법, 장기의 일부를 절제하거나 지방 흡입술과 같은 수술요법 그리고 에너지 대사 촉진제, 식욕억제제, 소화흡수 억제제 등을 사용하는 약물요법이 있다. 그러나 현재까지는 비만을 치료하는 방법 중 완전한 방법은 없으며 이러한 방법을 중단하였을 때 다시 체중이 증가되는 요요현상이 나타나거나 식이제한에 의한 영양불균형, 면역력 저하에 의한 감염 등 여러 가지 부작용이 나타나고 있다. 특히 약물요법의 경우, 우울증, 불면증, 소화장애 등 그 부작용이 다양하게 보고되고 있다. 따라서, 이러한 전통적인 방법 이외에 체중감소를 촉진하는 효과적이며 안전한 방법의 개발이 절실히 요구되고 있다.Treatment and prevention of obesity has been actively studied in various countries in various ways, currently being practiced to reduce the consumption of food by reducing the consumption of energy, diet to exercise energy to exercise energy, organ Surgery therapy such as ablation or liposuction, and drug therapy using energy metabolism accelerators, appetite suppressants, and digestive absorption inhibitors. However, until now, there is no complete method of treating obesity, and when these methods are discontinued, there are various side effects such as weight loss, yo-yo phenomenon, nutritional imbalance caused by dietary restriction, and infection caused by reduced immunity. In the case of drug therapy, various side effects such as depression, insomnia, and digestive disorders have been reported. Therefore, there is an urgent need to develop effective and safe methods for promoting weight loss in addition to these traditional methods.
복어는 저칼로리, 고단백질, 저지방과 각종 무기질 및 비타민이 들어 있는 다이어트 식품으로 유용하며, 대한민국 특허공개 제2002-91641호는 복어 알의 수성 추출액을 이용한 유방암, 위암, 폐암, 간암, 난소암 등의 암을 치료할 수 있는 약학 조성물을 개시한 바 있다. 그러나, 이러한 조성물이 항 비만 또는 항 당뇨 활성이 있는지에 대하여는 전혀개시 된 바 없다. Blowfish is useful as a diet food containing low calorie, high protein, low fat and various minerals and vitamins, and Korean Patent Publication No. 2002-91641 discloses breast cancer, stomach cancer, lung cancer, liver cancer and ovarian cancer using aqueous extracts of puffer fish eggs. Pharmaceutical compositions capable of treating cancer have been disclosed. However, there is no disclosure as to whether such compositions have anti-obesity or anti-diabetic activity.
본 발명자들은 당뇨 및 비만의 예방 및 치료에 유용한 천연 추출물을 개발하고자 연구하던 중, 놀랍게도 복어 독을 포함하고 있지 않는 제독된 복어의 수추출물이 비만을 억제하고 혈당 저하시키는 기능을 한다는 것을 발견하고 본 발명을 완 성하기에 이르렀다.The present inventors have been researching to develop a natural extract useful for the prevention and treatment of diabetes and obesity. Surprisingly, the present inventors have found that the water extract of the admired puffer fish, which does not contain blowfish poison, functions to inhibit obesity and lower blood sugar. Invented the invention.
본 발명의 목적은 복어 추출물을 포함하는 항 비만 활성을 갖는 비만의 예방 또는 치료용 약학 조성물을 제공하는 것이다. An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity having an anti-obesity activity, including a blowfish extract.
본 발명의 다른 목적은 복어 추출물을 포함하는 당뇨성 질환의 예방 또는 치료용 약학 조성물을 제공하는 것이다. Another object of the present invention to provide a pharmaceutical composition for the prevention or treatment of diabetic diseases comprising a blowfish extract.
본 발명은 제독된 복어를 증류하여 얻어지는 복어의 수추출물을 포함하는 비만 예방 또는 치료용 조성물을 제공한다.The present invention provides a composition for the prevention or treatment of obesity, including the water extract of puffer fish obtained by distilling the puffer fish.
본 발명은 또한, 제독된 복어를 증류하여 얻어지는 복어의 수추출물을 포함하는 당뇨성 질환의 예방 및 치료를 위한 약학 조성물을 제공한다. The present invention also provides a pharmaceutical composition for the prevention and treatment of diabetic diseases, including the water extract of puffer fish obtained by distilling the admired puffer fish.
본 발명의 일 구체예에서, 상기 당뇨성 질환은 만성 고혈당증 (hyperglycemia), 아테롬성 동맥경화증 (atherosclerosis), 미세혈관병증 (microangiopathy), 신장 질환, 심장 질환, 당뇨병성 망막증 (diabetic retinopathy) 및 다른 안과 질환 중 하나 이상이 포함되는 것이다. In one embodiment of the invention, the diabetic disease is chronic hyperglycemia, atherosclerosis, microangiopathy, kidney disease, heart disease, diabetic retinopathy and other ophthalmic diseases One or more of them are included.
본 발명에서 사용되는 복어는 분류학적으로 알려진 모든 복어를 사용할 수 있으며, 예를 들어 참복과, 불뚝복과. 거북복과, 가시복과 등에 속하는 복어들을 모두 사용할 수 있다. 상기에서 참복과에 속한 복어로서, 우리나라 수역에 서식하는 복어는 자지복, 검복, 까치복 등 18 종과 가시복의 1 종을 합쳐 19 종으로 알려져 있다. 복어에는 독성이 특히 강한 검복고, 자지복, 까치복 등이 있다.The puffer fish used in the present invention may use any taxonomically known puffer fish, for example, bokbokdae, firefish. You can use all of the puffer fish belonging to the turtle suit, thorn suit and the like. As a blowfish belonging to the bokbok family, the blowfish inhabiting the waters of Korea are known as 19 species including 18 species such as cock, sword, magpie, and 1 species of thorn. Blowfish are particularly toxic, including black robes, cocks and magpies.
본 발명에서 "제독된 복어"라 함은 복어의 간장, 생식선, 소화관, 피부 등에 들어있는 테트라도톡신이라는 신경독이 제거된 복어를 말하며, 통상 복어의 지느러미, 아가미, 눈을 제거하고 개복을 통하여 내장, 복어알, 그리고 피를 제거하여 흐르는 물에 1시간 동안 씻어서 제독할 수 있다.In the present invention, "adventured blowfish" refers to a blowfish that has been removed a neurotoxin called tetradotoxin contained in the liver, gonad, digestive tract, skin, etc. of the blowfish, and usually removes the fins, gills, and eyes of the blowfish Remove pufferfish, puffer fish, and blood and wash in running water for 1 hour to detoxify.
본 발명에서 사용되는 "복어의 수추출물"의 증류방법은 통상의 증류방법 (예를 들어, 단순 증류)에 따라 수행할 수 있으며, 바람직하게는 회분식 증류탑에서 100 ℃ 내지 150 ℃의 온도, 압력 1 내지 5 kgF/cm2에서 2 내지 7시간, 더욱 바람직하게는 125 ℃ 내지 135 ℃의 온도, 압력 2.8 내지 3.2 kgF/cm2에서 5 내지 7시간 동안 증류함으로써, 효과적으로 유용성분을 추출할 수 있다. 증류과정에서 물 중에 포함되는 복어의 양은 다량, 바람직하게는 물 1L 당 500 내지 1,500g의 양으로 포함되는 것이다. The distillation method of "water extract of puffer fish" used in the present invention can be carried out according to a conventional distillation method (for example, simple distillation), preferably in a batch distillation column, the temperature of 100 ℃ to 150 ℃, pressure 1 By distillation at 2 to 7 hours at 5 kgF / cm 2 , more preferably at a temperature of 125 ℃ to 135 ℃, 5 to 7 hours at a pressure of 2.8 to 3.2 kgF / cm 2 , it is possible to extract the useful components effectively. The amount of blowfish contained in the water in the distillation process is a large amount, preferably in an amount of 500 to 1,500 g per 1 L of water.
본 발명에서 사용되는 수추출물은 제독된 복어를 물 1L 당 500 내지 1,500g의 많은 양으로 포함하는 혼합물으로부터 증류되기 때문에 복어에 포함되어 있는 유용 성분, 특히 단백질 및 펩타이드를 액상과 고상으로 분리할 수 있도록 한다. 특히, 복어 속에 있는 유효한 성분 (예: 유용 펩타이드, 과기부 2003년도 신기술 융합과제: "유용 펩타이드 리간드의 발굴과 정보화 및 응용에 관한 연구"를 참조)은 아주 적은 양으로 존재하여 적은 양의 복어로부터 유용한 성분을 얻기가 힘들기 때문에, 많은 양의 복어를 사용함으로써 고농축 유효성분을 얻고자 하는 것이다. Since the water extract used in the present invention is distilled from a mixture containing a large amount of deodorized puffer fish in the amount of 500 to 1,500 g per liter of water, it is possible to separate the useful components, particularly proteins and peptides contained in the puffer fish, in liquid and solid phase. Make sure In particular, active ingredients in pufferfish (e.g., useful peptides, widows, new technology fusion projects 2003: see "Discovery, Information and Application of Useful Peptide Ligands") are present in very small quantities and are useful in small amounts of puffer fish. Since it is difficult to obtain the ingredients, it is intended to obtain a highly concentrated active ingredient by using a large amount of blowfish.
본 발명의 조성물에는 약제학적으로 허용가능한 첨가제가 포함될 수 있다. 상기 첨가제는 통상적인 부형제, 붕해제, 결합제, 활택제, 현탁화제 등 중에서 1종 또는 2종 이상을 선택적으로 사용할 수 있다. 예를 들어, 본 발명의 조성물을 정제 또는 경질캅셀제 등의 고형제형으로 제조할 경우, 부형제로서 미결정 셀룰로오즈, 유당, 저치환도 히드록시셀룰로오즈 등이 사용될 수 있고, 붕해제로서 전분글리콜산 나트륨, 무수인산일수소 칼슘 등이 사용될 수 있다. 결합제로는 폴리비닐피롤리돈, 저치환도 히드록시프로필셀룰로오즈, 히드록시프로필셀룰로오즈 등이 사용될 수 있고, 활택제로서는 스테아린산 마그네슘, 이산화규소, 탈크 등으로부터 선택하여 사용할 수 있다. 또한, 현탁화제로는 약제학 분야에서 통상적으로 사용되는 계면활성제 (예를 들어, 소르비탄 에스테르류, 또는 폴리소르베이트류 등)를 사용할 수 있다.Compositions of the present invention may include pharmaceutically acceptable additives. The additives may optionally be used one or two or more of conventional excipients, disintegrants, binders, lubricants, suspending agents and the like. For example, when the composition of the present invention is prepared in a solid form such as tablets or hard capsules, microcrystalline cellulose, lactose, low-substituted hydroxycellulose and the like can be used as excipients, sodium starch glycolate, anhydrous as a disintegrant. Calcium monohydrogen phosphate may be used. As the binder, polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose and the like can be used. The lubricant can be selected from magnesium stearate, silicon dioxide, talc and the like. In addition, as the suspending agent, surfactants (eg, sorbitan esters, polysorbates, etc.) commonly used in the pharmaceutical field may be used.
본 발명의 조성물은 고형 및 액상 형태를 포함한 다양한 형태의 제형으로 제제화할 수 있으며, 이들 제형은 정제, 캅셀제 (경질 또는 연질), 액제 (solution), 현탁제, 유제, 및 시럽제 등을 포함한다. 바람직하게는 액제, 현탁제, 유제, 및 시럽제 등의 액체 제형을 가질 수 있으며, 기능성 식품으로 제조할 수도 있다.The compositions of the present invention can be formulated in a variety of forms, including solid and liquid forms, which include tablets, capsules (hard or soft), solutions, suspensions, emulsions, syrups and the like. It may preferably have liquid formulations such as liquids, suspensions, emulsions, and syrups, and may also be prepared as a functional food.
본 발명의 조성물은 경구 또는 비경구를 포함한 다양한 투여방법으로 투여될 수 있으며, 바람직하게는 경구로 투여될 수 있다. 본 발명의 조성물은 비만의 예방 또는 치료, 또는 당뇨성 질환의 예방 또는 치료가 필요한 사람에게 1일 0.1 내지 1,000 mg/kg의 범위로 투여될 수 있다. 그러나, 상기 투여량은 나이, 연령 및 성별과 같은 상태 및 질병의 경중 등에 따라 적당한 양으로 조정하여 투여될 수 있으며, 이러한 투여량은 임상적으로 환자의 치료 또는 예방에 종사하는 당업자라면 용 이하게 조정할 수 있다.The composition of the present invention may be administered by various methods of administration, including oral or parenteral, and may be preferably administered orally. The composition of the present invention can be administered to a person in need of prevention or treatment of obesity, or prevention or treatment of diabetic disease in the range of 0.1 to 1,000 mg / kg per day. However, the dosage may be adjusted to an appropriate amount depending on the condition such as age, age and sex and the severity of the disease, such dosage is easy for those skilled in the art clinically engaged in the treatment or prevention of patients. I can adjust it.
이하 본 발명을 실시예를 통하여 보다 구체적으로 설명한다. 그러나, 이 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이 실시예에 한정되는 것은 아니다. Hereinafter, the present invention will be described in more detail with reference to Examples. However, this embodiment is for illustrative purposes only and the scope of the present invention is not limited to this embodiment.
실시예 1Example 1
참복 (검자주복 : Fugu rubripes rubripes)의 지느러미, 아가미, 눈을 제거하고, 개복하여 내장, 복어알, 그리고 피를 제거하여 흐르는 물에 1 시간 동안 씻어서 제독처리하였다. 제독된 복어 30 kg을 물 20 L 중에 첨가하였다. 상기 혼합물을 원통형 회분식 증류탑 (55 L 용량)에 주입하였다. 다음으로, 온도 130 ℃, 압력 3 kgF/cm2의 조건에서 약 6시간 동안 증류를 수행하였다.The fins, gills, and eyes of the abalone ( Fugu rubripes rubripes ) were removed, and the abdominal glands, puffer fish, and blood were removed, washed in running water for 1 hour, and detoxified. 30 kg of decontaminated blowfish was added to 20 L of water. The mixture was injected into a cylindrical batch distillation column (55 L capacity). Next, distillation was performed for about 6 hours at the temperature of 130 degreeC and the pressure of 3 kgF / cm <2> .
그 결과, 탑상으로는 복어의 유효한 단백질, 펩티드 등을 포함하는 액상 추출물 30 L를 얻었으며, 탑의 하단에서는 증류되고 남은 고형 물질 20 kg을 얻었다. As a result, 30 L of the liquid extract containing the effective protein of the puffer fish, peptides, etc. were obtained on the tower, and 20 kg of the remaining solid material was obtained at the bottom of the tower.
이렇게 탑상으로부터 얻어진 액상 추출물에 대하여 항 비만 및 항 당뇨 활성이 있는지 여부를 조사하였다. Thus, the liquid extract obtained from the tower phase was investigated whether there is anti-obesity and anti-diabetic activity.
실시예 2 : 복어 추출물의 항 비만 또는 항 당뇨 활성의 확인Example 2 Confirmation of Anti-Obesity or Anti-Diabetes Activity of Pufferfish Extract
본 실시예에서는 실시예 1에서 준비된 복어 수추출물을 고지방 식이와 함께 생쥐에 5개월 동안 투여하고, 체중의 변화를 관찰함으로써 비만성 당뇨병이 유발되 는지를 확인하였다. In this example, the puffer fish extract prepared in Example 1 was administered to mice with high fat diet for 5 months, and the change in body weight was observed to determine whether obesity diabetes was induced.
(1) 복어 수추출물이 비만 및 비만성 당뇨병의 유발에 미치는 영향(1) Effect of puffer fish extract on the induction of obesity and obesity diabetes
6 주령 생쥐 C57BL/6 (male)를 각 군 당 7 내지 8 마리로 구성되는 2개 군으로 나눈 뒤 8 주 동안 고지방 식이로 전처리한 후 아래와 같은 음식을 20주 동안 투여하였고, 21주 이후부터는 고지방 식이를 정상 식이로 치환하였다.Six-week-old mice, C57BL / 6 (male), were divided into two groups of 7 to 8 animals per group, pre-treated with a high-fat diet for 8 weeks, and then given the following foods for 20 weeks. The diet was replaced with a normal diet.
제1 군: 고지방 음식 (60 kcal % 지방, 단백질 20 kcal %, 탄수화물 20 kcal % 으로 구성되는 설치류 식이)+ 복어 추출물 25cc/g/dGroup 1: High-fat food (rodent diet consisting of 60 kcal% fat, 20 kcal% protein, 20 kcal% carbohydrates) + Pufferfish extract 25cc / g / d
제2 군: 고지방 음식 (60 kcal % 지방, 단백질 20 kcal %, 탄수화물 20 kcal % 으로 구성되는 설치류 식이)Group 2: High fat foods (rodent diet consisting of 60 kcal% fat, 20 kcal% protein, 20 kcal% carbohydrates)
식이는 대략 한 마리당 하루에 2.2g 정도 섭취시켰다. 이는 일주일에 100g씩을 공급하고, 남은 먹이 무게를 측정함으로써 계산된 값이다. The diet consumed about 2.2 grams per day per animal. This is calculated by feeding 100g a week and measuring the remaining food weight.
고지방 음식이란 총 중량에 대하여 60 중량%가 지방으로 이루어진 음식을 말한다. 상기한 바와 같은 음식을 제공하였으며, 제1 군의 경우에는 1일 1회 복어 추출물을 경구 투여하였다. High fat food refers to food consisting of 60% by weight of the total weight. Food as described above was provided, and in the case of the first group was blowfish oral administration once a day.
투여 후 매 1주일 마다 쥐의 체중을 측정하였다. 표 1은 본 발명의 복어 추출물을 생쥐에 투여하고 매 1 주일 마다 체중을 측정하여 체중의 변화를 관찰한 결과를 나타내는 표이다. Mice were weighed every week after administration. Table 1 is a table showing the results of observing the change in weight by administering the blowfish extract of the present invention to the mice and measuring the weight every week.
표 1.Table 1.
표 1 (계속)Table 1 (continued)
표 1 (계속)Table 1 (continued)
표 1에 나타낸 바와 같이, 복어 추출물을 함유하는 고지방 식이를 생쥐에게 투여하는 경우, 체중이 상대적으로 감소하였다. 이는 본 발명의 복어 추출물이 비만 예방 또는 치료 효과가 있다는 것을 의미한다. As shown in Table 1, when a high fat diet containing blowfish extract was administered to mice, body weight was relatively decreased. This means that the blowfish extract of the present invention has an obesity prevention or treatment effect.
(2) 복어 수추출물이 혈당에 미치는 영향(2) Effect of puffer fish extract on blood sugar
본 절에서는 상기 제 (1)절에서 관찰된 바와 같이, 본 발명의 복어 추출물이 정상 음식물과 함께 생쥐에 투여되는 경우 생쥐의 체중 증가를 억제하는 효과가 비만성 당뇨병과 연관성이 있는지를 확인하기 위하여, 복어 추출물을 투여한 생쥐에 대하여 혈당을 측정하였다. In this section, as observed in paragraph (1) above, when the puffer fish extract of the present invention is administered to mice with normal food, to determine whether the effect of inhibiting the weight gain of mice is associated with obesity diabetes Blood glucose levels were measured in the mice to which the puffer fish extract was administered.
구체적으로, 복어 추출물을 투여하기 시작한 주를 1주로 하여 각 생쥐군을 실험 개시 12 시간 전부터 절식시킨 다음 혈장 포도당 농도를 측정하였다. Specifically, each group of mice was fasted 12 hours before the start of the experiment, and the plasma glucose concentrations were measured.
표 2. Table 2.
표 2에 나타낸 바와 같이, 복어 추출물 투여 초기에는 혈당의 차이가 없었으나, 16주부터 조금씩 차이가 나기 시작하였고, 20주 이후부터는 복어 추출물을 함께 투여한 군의 혈장 포도당 농도가 물을 함께 투여한 군에 비하여 약 20% 정도 낮았다. As shown in Table 2, there was no difference in blood glucose at the beginning of the blowfish extract administration, but began to change slightly at 16 weeks, and after 20 weeks, the plasma glucose concentration of the group where the blowfish extract was administered together was administered with water. It was about 20% lower than the group.
도 1은 23주간 복어 추출물을 투여한 생쥐로부터 간을 적출하여 내고, 여기서 단백질을 얻어 시료로 하여 FAS (fatty acid synthase)에 대하여 웨스턴 블롯 분석실험을 한 결과를 나타내는 도면이다. 튜불린 (tubulin)은 지속적으로 생체 내에서 발현되는 단백질로 동량의 단백질이 사용되었는지 알아보기 위해서, 즉 실험의 정확성을 확인하기 위하여 사용하였다. FAS는 간에서 지방산 합성 초기에 작용하는 효소로써, 실험군에서 FAS의 발현이 현저하게 저하된 것으로 볼 때 복어추출물에 의하여 지방산 합성이 억제되는 것으로 보이며, 이는 체내 지방 저장을 감소시키는 것으로 여겨진다. 식이에 조절받는 FAS는 간에서 지방산 합성에 관여하는 효소이다. 복어추출물을 먹인 실험군에서 FAS의 발현 (basal level) 이 현저하게 저하된 것으로 볼 때 복어추출물에 의하여 지방산 합성이 억제되는 것으로 보이며, 이는 체내 지방 축적을 감소시키는 것으로 여겨진다. 1 is a diagram showing the results of Western blot analysis of FAS (fatty acid synthase) using a sample obtained by extracting the liver from the mice to which the pufferfish extract was administered for 23 weeks. Tubulin is a protein that is continuously expressed in vivo, and used to determine whether the same amount of protein was used, that is, to confirm the accuracy of the experiment. FAS is an enzyme that acts at the early stage of fatty acid synthesis in the liver, and it seems that fatty acid synthesis is suppressed by the puffer fish extract, which indicates that the expression of FAS in the experimental group is markedly decreased, which is believed to reduce fat storage in the body. Dietaryly regulated FAS is an enzyme involved in fatty acid synthesis in the liver. In the group fed the blowfish extract, the expression of FAS (basal level) was significantly lowered, and the fatty acid synthesis seems to be inhibited by the blowfish extract, which seems to reduce the accumulation of fat in the body.
실시예 3 : 복어 추출물의 체중증가 억제 효과Example 3 Inhibitory Effect of Blowfish Extract on Weight Gain
본 실시예에서는 실시예 1에서 준비된 복어 수추출물을 고지방 정상 식이와 함께 생쥐에 6개월 동안 투여하고, 체중의 변화를 관찰함으로써 비만성 당뇨병이 유발되는지를 확인하였다. In this example, the puffer fish extract prepared in Example 1 was administered to mice with a high fat normal diet for 6 months, and the change in body weight was observed to determine whether obesity diabetes was induced.
(1) 복어 수추출물이 체중에 미치는 영향(1) Effect of Pufferfish Extract on Body Weight
6 주령 생쥐 C57BL/6 (male)를 각 군 당 7 내지 8 마리로 구성되는 2개 군으로 나눈 뒤 정상 식이를 30주 동안 투여하였다.Six-week-old mice C57BL / 6 (male) were divided into two groups consisting of 7 to 8 animals per group, followed by a normal diet for 30 weeks.
제1 군: 정상 식이 + 복어 추출물 25cc/g/dGroup 1: Normal Diet + Blowfish Extract 25cc / g / d
제2 군: 정상 식이Group 2: Normal Diet
식이는 대략 한 마리당 하루에 2.2g 정도 섭취시켰다. 이는 일주일에 100g씩을 공급하고, 남은 먹이 무게를 측정함으로써 계산된 값이다. The diet consumed about 2.2 grams per day per animal. This is calculated by feeding 100g a week and measuring the remaining food weight.
투여 후 매 1주일 마다 쥐의 체중을 측정하였다. 표 3은 본 발명의 복어 추출물을 30주 동안 생쥐에 투여하고 매 1 주일 마다 체중을 측정하여 체중의 변화를 관찰한 결과를 나타내는 표이다. 또한, 도 2는 표 3의 결과를 도면으로 나타낸 것이다. Mice were weighed every week after administration. Table 3 is a table showing the results of observing the change in weight by administering the blowfish extract of the present invention to the mouse for 30 weeks and measuring the weight every week. 2 shows the result of Table 3 by drawing.
표 3.Table 3.
표 3에 나타낸 바와 같이, 생쥐에게 정상식이를 섭취시키면서 복어 수추출물을 30 주 동안 먹이면서 체중 변화를 비교한 결과, 복어 수추출물을 먹인 경우가 대조군에 비하여 체중 증가가 약 14% 정도 억제됨을 확인하였다. 따라서, 본 발명의 복어 수추출물은 체중 증가를 억제하는데 효과가 있음을 알 수 있다. As shown in Table 3, the comparison of the weight change while feeding the puffer fish extract for 30 weeks while ingesting the normal diet in the mice, confirmed that the weight gain is suppressed by about 14% compared to the control group It was. Therefore, it can be seen that the puffer fish extract of the present invention is effective in suppressing weight gain.
본 발명의 비만 예방 또는 치료용 조성물에 의하면, 개체의 비만을 예방 또는 치료할 수 있다. According to the composition for preventing or treating obesity, the obesity of an individual can be prevented or treated.
본 발명의 당뇨성 질환의 예방 및 치료를 위한 약학 조성물에 의하면, 당뇨병을 예방 또는 치료할 수 있다. According to the pharmaceutical composition for the prevention and treatment of diabetic diseases of the present invention, diabetes can be prevented or treated.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050071062A KR100732614B1 (en) | 2005-08-03 | 2005-08-03 | Pharmaceutical composition for the prevention or treatment of obesity or diabetic disease comprising blowfish extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050071062A KR100732614B1 (en) | 2005-08-03 | 2005-08-03 | Pharmaceutical composition for the prevention or treatment of obesity or diabetic disease comprising blowfish extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070016417A KR20070016417A (en) | 2007-02-08 |
KR100732614B1 true KR100732614B1 (en) | 2007-06-27 |
Family
ID=41634077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050071062A Expired - Fee Related KR100732614B1 (en) | 2005-08-03 | 2005-08-03 | Pharmaceutical composition for the prevention or treatment of obesity or diabetic disease comprising blowfish extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100732614B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100839586B1 (en) | 2007-01-19 | 2008-06-19 | 이상길 | Composition containing blowfish extract using protease as an active ingredient and method for preparing the same |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102219426B1 (en) | 2019-01-03 | 2021-02-25 | 대한바이오팜 주식회사 | Anti-Metastasis Composition comprising Pufferfish Extract |
KR20210084028A (en) | 2019-12-27 | 2021-07-07 | 대한바이오팜 주식회사 | Composition comprising Pufferfish Extract for Combination Therapy with Anticancer Drugs |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004053608A (en) * | 2002-07-23 | 2004-02-19 | F Hoffmann La Roche Ag | Method and apparatus for confirming concentration position in gel and cutting out that part |
-
2005
- 2005-08-03 KR KR1020050071062A patent/KR100732614B1/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004053608A (en) * | 2002-07-23 | 2004-02-19 | F Hoffmann La Roche Ag | Method and apparatus for confirming concentration position in gel and cutting out that part |
Non-Patent Citations (1)
Title |
---|
한국공개특허공보 제2004-53608 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100839586B1 (en) | 2007-01-19 | 2008-06-19 | 이상길 | Composition containing blowfish extract using protease as an active ingredient and method for preparing the same |
Also Published As
Publication number | Publication date |
---|---|
KR20070016417A (en) | 2007-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100195886B1 (en) | Pharmaceutical composition for treating diabetes mellitus | |
JP2961045B2 (en) | Intestinal mucosa enhancement promoter | |
KR102271821B1 (en) | Composition Comprising Orlistat and Akkermansia muciniphila EB-AMDK19 | |
CN108025007A (en) | Trimetazidine is preparing the purposes in preventing hepatic medicine | |
Qadri et al. | Diabetes mellitus in dogs and its associated complications: A review | |
JP6445686B2 (en) | Anti-diabetic effect of dipenoside 75 | |
CA3022247C (en) | Composition for treating diabetic disease | |
TWI679014B (en) | Use of liver hydrolysate for producing pancreatic function improving agent | |
CN103446166B (en) | Hepatic function remedial agent | |
WO2019109551A1 (en) | Pharmaceutical composition containing magnesium aluminum carbonate and pharmaceutical use | |
KR100732614B1 (en) | Pharmaceutical composition for the prevention or treatment of obesity or diabetic disease comprising blowfish extract | |
CN112755035A (en) | Application of tauroursodeoxycholic acid in treatment of neonatal necrotizing enterocolitis | |
JPWO2005041995A1 (en) | α-Glucosidase activity inhibitor | |
US10342852B2 (en) | Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein | |
CN110946986A (en) | Application of an oligopeptide in the preparation of a drug for the prevention and treatment of nonalcoholic fatty liver disease | |
KR100542809B1 (en) | Herbal medicine composition for lowering blood sugar, preparation method thereof, and pharmaceutical preparation comprising the same | |
CN106727480B (en) | Fex-3 is preparing the application in anti-obesity drug | |
WO2022061962A1 (en) | Method for effectively intervening diabetes by using l-type amino acid transporter inhibitor or antagonist | |
JP2010168399A (en) | Pharmaceutical for controlling elevation of blood sugar | |
CN106619605A (en) | Medicinal application of corylin | |
JP2009062348A (en) | Hypoglycemic action and blood sugar level elevation-suppressive action by seed ingredient of kenafs (kenaf and roselle) | |
CN101327204A (en) | The role of rhein in preventing and treating fatty liver | |
CN110420270A (en) | A kind of functional composition containing camellia oil and fish oil and its application | |
US12280084B1 (en) | Fenugreek formulation for lowering blood glucose and weight loss | |
RU2829635C1 (en) | Pharmaceutical composition based on 5-pentylresorcinol with hypoglycemic effect and body weight reduction effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20050803 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20061019 Patent event code: PE09021S01D |
|
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20061215 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
AMND | Amendment | ||
PG1501 | Laying open of application | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20070319 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20061019 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
PJ0201 | Trial against decision of rejection |
Patent event date: 20070418 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20070319 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20070601 Appeal identifier: 2007101004094 Request date: 20070418 |
|
PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20070418 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20070418 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20061219 Patent event code: PB09011R02I |
|
B701 | Decision to grant | ||
PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 20070601 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20070523 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20070620 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20070621 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
PG1701 | Publication of correction | ||
PR1001 | Payment of annual fee |
Payment date: 20100622 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20110519 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20120607 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20120607 Start annual number: 6 End annual number: 6 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20140509 |